title: Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study.
abstract: To investigate whether sitagliptin affects copeptin and osmolality, suggesting arginine vasopressin activation and a potential for fluid retention, compared with placebo, in patients with a recent acute coronary syndrome and newly discovered type 2 diabetes or impaired glucose tolerance. A second aim was to confirm whether copeptin correlated with insulin-like growth factor binding protein-1.
  
  
  
  Fasting blood samples were used from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction trial, in which patients recently hospitalized due to acute coronary syndrome and with newly detected abnormal glucose tolerance were randomized to sitagliptin 100 mg once daily (n = 34) or placebo (n = 37). Copeptin, osmolality and insulin-like growth factor binding protein-1 were analysed at baseline and after 12 weeks.
  
  
  
  Copeptin and osmolality were unaffected by sitagliptin. There was no correlation between copeptin and insulin-like growth factor binding protein-1.
  
  
  
  Sitagliptin therapy does not appear to be related to activation of the arginine vasopressin system.
authors.affiliation: Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden lisa.arnetz@karolinska.se.
authors.forename: Lisa
authors.initials: L
authors.lastname: Arnetz
authors.affiliation: Department of Medicine, Cardiology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Camilla
authors.initials: C
authors.lastname: Hage
authors.affiliation: Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Kerstin
authors.initials: K
authors.lastname: Brismar
authors.affiliation: Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Sergiu-Bogdan
authors.initials: SB
authors.lastname: Catrina
authors.affiliation: Department of Medicine, Cardiology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Anna
authors.initials: A
authors.lastname: Norhammar
authors.affiliation: Division of Cardiovascular Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
authors.forename: Pia
authors.initials: P
authors.lastname: Lundman
authors.affiliation: Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.
authors.forename: Märit
authors.initials: M
authors.lastname: Wallander
authors.affiliation: Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Lars
authors.initials: L
authors.lastname: Ryden
authors.affiliation: Department of Medicine, Cardiology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Linda
authors.initials: L
authors.lastname: Mellbin
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006020:Glycopeptides / Q000097:blood*; D006760:Hospitalization; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood*; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D009481:Neurophysins / Q000378:metabolism; D009994:Osmolar Concentration; D011498:Protein Precursors / Q000378:metabolism; D000068900:Sitagliptin Phosphate / Q000008:administration & dosage* / Q000009:adverse effects; D013548:Sweden; D013997:Time Factors; D016896:Treatment Outcome; D014667:Vasopressins / Q000378:metabolism; D014882:Water-Electrolyte Balance / Q000187:drug effects
chemical_list: C438657:AVP protein, human; D015415:Biomarkers; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006020:Glycopeptides; C032231:IGFBP1 protein, human; D018970:Insulin-Like Growth Factor Binding Protein 1; D009481:Neurophysins; D011498:Protein Precursors; C048197:copeptins; D014667:Vasopressins; D000068900:Sitagliptin Phosphate
keywords: Diabetes; acute coronary syndrome; copeptin; insulin-like growth factor binding protein-1; osmolality; sitagliptin